+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Markets for Treatment and Diagnosis of Sexually Transmitted Diseases

  • ID: 4616790
  • Report
  • Region: Global
  • 236 Pages
  • BCC Research
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Biomerieux, Inc.
  • Cepheid Inc.
  • Glaxosmithkline Plc.
  • Hologic Inc.
  • Novartis Ag
  • MORE
Report Scope:

This report organizes information from diverse sources into a comprehensive report that includes sections on disease overviews, industry structure, diagnostic kits, treatment interventions, pharmaceutical products, emerging technologies, regulations, reimbursement and patents. The scope of this the report includes an overview of the global market scenario for diagnosis and treatments of sexually transmitted disease with base year data of 2017, estimations for 2018 and forecast for 2019-2023 using projections of CAGR. Market data in value terms is provided at global, regional and country levels for disease areas and treatment by drug class. Market data for sexually transmitted disease diagnostics is provided for regional levels, with details on test types.

The report focuses on key sectional assessments for major disease areas such as chlamydia, genital herpes, HIV and hepatitis, among others, and provides detailed analysis of epidemiology, historic and current disease incidence trends, therapeutic interventions and diagnostic overview. It forecasts the global market by drug class for treatment of STDs and discusses market data for antibiotics, antivirals/antiretrovirals and other treatments. Diagnostic test types such as enzyme immunoassays (EIA) and ELISA, PCR, rapid diagnostics and others, are detailed with market data current and forecasts.

Market dynamics such as drivers, restraints and trends are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific, Latin America and the Middle East. The regional overviews provide information on the epidemiology of sexually transmitted disease by country and region and also details market data for each region. The regulatory scenario is discussed for United States, Europe, Japan and China to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe, and Japan to provide an overview to our readers. Pipeline analysis and scenarios are discussed for major disease to provide details on the major pipeline developments. The competitive landscape discusses the major manufacturers involved in the sexually transmitted disease therapeutics market, key developments and product offerings.

The Report Includes:
  • 45 data tables and 53 additional tables
  • An overview of the global market for diagnosis and treatments of sexually transmitted diseases
  • Country specific data and analysis for United States, Canada, Mexico, France, Germany, U.K., Spain, China, India, Japan, and Middle East and Africa
  • Coverage of major disease areas, and a detailed analysis of historic and current disease incidence trends
  • Discussion about market dynamics such as drivers, restraints, and trends
  • Information on the regulations for new drug launches and diagnostic kits for United States, Europe, Japan and China
  • Detailed profiles of the major market players, including Abbott Laboratories, AbbVie Inc., Agilent Technologies, Inc., Biomerieux, Inc., Bio-Rad Laboratories Inc., Novartis Ag, Pfizer Inc., Promega Corp., and Thermo Fisher Scientific, Inc.
Membership Price:

Contact us for membership pricing.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Biomerieux, Inc.
  • Cepheid Inc.
  • Glaxosmithkline Plc.
  • Hologic Inc.
  • Novartis Ag
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Global Market Overview and Trends

  • Overview of Sexually Transmitted Diseases and Definitions
  • Sexually Transmitted Diseases and Pregnancy
  • Screening Programs and Guidelines
  • Mobile HIV Testing in Brazil
  • Benzathine Penicillin Drug Shortage
  • Trends in Global Transmission of STDs
  • Increasing Incidence of STDs
  • STD Awareness and Screening Services
  • Development of Test Kits with High Sensitivity for Low Resource Settings
  • Challenges
  • Underestimating the Risk of Contracting the Disease
  • Social Stigma Associated with STDs
  • Rising Incidence of Antibiotic Resistance
  • Lack of Prenatal Screening for STDs

Chapter 4 Disease Overview

  • Introduction
  • Chlamydia
  • Overview
  • Epidemiology
  • Diagnosis
  • Treatments
  • Genital Herpes
  • Overview
  • Epidemiology
  • Diagnosis
  • Treatments
  • Gonorrhea
  • Overview
  • Epidemiology
  • Diagnosis
  • Treatments
  • Hepatitis A, B and C
  • Overview
  • Epidemiology
  • Diagnosis
  • Treatments
  • Market Size
  • HIV/AIDS
  • Overview
  • Epidemiology
  • Diagnosis
  • Treatments
  • Market Size and Forecast
  • HPV
  • Overview
  • Diagnosis
  • Treatments
  • Syphilis
  • Overview
  • Epidemiology
  • Diagnosis
  • Treatments
  • Others
  • Overview
  • Market Analysis

Chapter 5 STD Diagnosis and Treatment Options

  • Introduction to STD Diagnostics, by Test Type
  • Enzyme Immunoassay (EIA) and ELISA
  • Polymerase Chain Reaction (PCR)
  • Rapid Diagnostics Tests (RDTs)
  • Others
  • Introduction to Treatment by Drug Class
  • Antibiotics/Antibacterial
  • Antiviral/ Antiretrovirals
  • Others

Chapter 6 The North American Market Breakdown

  • Overview of North American Market
  • United States
  • Canada
  • Mexico

Chapter 7 The European Market Breakdown

  • Overview of the European Market
  • Chlamydia
  • United Kingdom
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe

Chapter 8 The Asia-Pacific Market Breakdown

  • Overview of The Asia-Pacific Market
  • Market Analysis
  • Key Trends in STI Prevention
  • Legal Obstructions
  • Social Stigma and Discrimination
  • China
  • Prevention Programs
  • Legal and Punitive Barriers
  • Market Analysis
  • Japan
  • Chlamydia
  • Genital Herpes
  • Gonorrhea
  • Syphilis
  • Market Analysis
  • India
  • Launch of Hepcinat Plus for Hepatitis C in India
  • Aurobindo Pharma Files for Dolutegravir Generic
  • Market Analysis
  • South Korea
  • Market Analysis
  • Rest of Asia-Pacific
  • HIV/AIDS
  • Market Analysis

Chapter 9 Rest of World Market Breakdown

  • The Rest of World Overview
  • South American Market Overview
  • Middle East and Africa Overview

Chapter 10 Regulatory Structure

  • Overview of Regulations
  • United States
  • Europe
  • Japan
  • China
  • Overview of Pricing and Reimbursement
  • United States
  • Europe
  • Japan

Chapter 11 Pipeline Analysis

  • HIV Pipeline Overview
  • List of Drugs in HIV Pipeline
  • Hepatitis C Pipeline Overview
  • Several Drug Combinations Discontinued
  • Gonorrhea Pipeline Overview
  • Late-Stage Pipeline Molecules
  • Doravirine (MK-1439, DOR)
  • Drugs to Gain Marketing Authorization
  • Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
  • Dolutegravir/Lamivudine (ViiV Healthcare)
  • Aikening (albuvirtide for injection) (Frontier Biotechnology Inc.)
  • Elpida (elsulfavirine) (Viriom, Inc.)
  • Isentress HD (Raltegravir) (Merck & Co., Inc.)

Chapter 12 Competitive Landscape and Key Developments

  • Market Structure Analysis
  • Patent Analysis
  • Key Developments
  • Mergers and Acquisitions
  • Development of Innovative Products/Novel Product Launches
  • Agreement, Collaboration and Partnerships

Chapter 13 Company Profiles

  • ABBOTT LABORATORIES
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • ABBVIE INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • AGILENT TECHNOLOGIES, INC.
  • Company Overview
  • Financials
  • BECTON, DICKINSON AND COMPANY
  • Company Overview
  • Product Information
  • Key Developments and Strategies
  • Financials
  • BIOMERIEUX, INC.
  • Company Overview
  • Product Information
  • BIO-RAD LABORATORIES, INC
  • Company Overview
  • Product Information
  • BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
  • Company Overview
  • Financials
  • Development and Strategies
  • BRISTOL-MYERS SQUIBB COMPANY
  • Company Overview
  • Product Information
  • Financials
  • CEPHEID INC.
  • Company Overview
  • GILEAD SCIENCES, INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • GLAXOSMITHKLINE PLC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • HOFFMANN-LA ROCHE INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • HOLOGIC INC.
  • Company Overview
  • Product Information
  • Financials
  • JANSSEN PHARMACEUTICALS, INC.
  • Company Overview
  • Product Information
  • Developments and Strategies
  • Financials
  • MERCK & CO., INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • MERIDIAN LIFE SCIENCE INC.
  • Company Overview
  • Product Information
  • NOVARTIS AG
  • Company Overview
  • Product Information
  • Financials
  • PFIZER INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • PROMEGA CORP.
  • Company Overview
  • QIAGEN N.V.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • QUIDEL CORP
  • Company Overview
  • Product Information
  • THERMO FISHER SCIENTIFIC, INC.
  • Company Overview
  • Product Information
  • Financials

Chapter 14 Appendix: Abbreviations

  • Abbreviations

List of Tables
Summary Table A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
Summary Table B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2023
Table 1: Sexually Transmitted Diseases, by Different Pathogens
Table 2: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
Table 3: Chlamydia Incidence, 2012-2017
Table 4: Chlamydia Diagnostic Products, Brand Name and Manufacturer
Table 5: Drugs for Chlamydia Treatment
Table 6: Global HSV-1 Prevalence, Aged 0-49 years, 2012
Table 7: Global HSV-1 Incidence, Aged 0-49 years, 2012
Table 8: Genital Herpes Diagnostic Products, Brand Name and Manufacturer
Table 9: Gonorrhea Epidemiology, 2012-2017
Table 10: Gonorrhea Diagnostic Products, Brand Name and Manufacturer
Table 11: Drug for Gonorrhea Treatment
Table 12: Hepatitis A Incidence
Table 13: Hepatitis B Incidence
Table 14: Hepatitis C Incidence
Table 15: Hepatitis B and C Diagnostic Products, Brand Name and Manufacturer
Table 16: Hepatitis B Medications by Brand Name, Generic Name, Manufacturer, Indication
Table 17: Hepatitis C Medications by Brand Name, Generic Name, Manufacturer, Indication
Table 18: Global Market for Hepatitis Therapeutics, by Region, Through 2023
Table 19: HIV Prognosis
Table 20: HIV Incidence
Table 21: HIV Incidence
Table 22: HIV/AIDS Diagnostic Products, Brand Name and Manufacturer
Table 23: HIV Medications by Drug Class, Generic Name, Brand Name
Table 24: Global Market for HIV/AIDS Therapeutics, by Region, Through 2023
Table 25: HPV Diagnostic Products, Brand Name and Manufacturer
Table 26: HPV Vaccines
Table 27: Syphilis Incidence
Table 28: Infectious Syphilis Incidence, by Country, 2012-2014
Table 29: Syphilis Diagnostic Products, Brand Name and Manufacturer
Table 30: Drug for Syphilis Treatment
Table 31: Trichomonas Vaginalis Diagnostic Assay, Brand Name, Type and Manufacturer
Table 32: Bacterial Vaginosis Diagnostic Products, Brand Name and Manufacturer
Table 33: Global Market for Other Therapeutics, by Region, Through 2023
Table 34: Global Market for Sexually Transmitted Disease Diagnostics, by Region, Through 2023
Table 35: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, Through 2023
Table 36: Antibacterial Drugs for STD
Table 37: Global Market for Antibiotics, by Region, Through 2023
Table 38: Global Market for Antiviral/Antiretroviral drugs, by Region, Through 2023
Table 39: Global Market for Other Drug Class, by Region, Through 2023
Table 40: North American Estimated HBsAG Seroprevalence, 2016
Table 41: North American Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
Table 42: North American Market for Sexually Transmitted Disease Therapeutics, by Drug Class, Through 2023
Table 43: United States Historic and Current Chancroid Trend, Incidence, 1990-2016
Table 44: European Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
Table 45: European Market for Sexually Transmitted Disease Therapeutics, by Drug Class, Through 2023
Table 46: Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
Table 47: Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, by Drug Class, Through 2023
Table 48: South American, Middle East and Africa HIV/AIDS Epidemiology, 2016
Table 49: South American, Middle East & Africa Market for Sexually Transmitted Disease Therapeutics, by Disease Area, Through 2023
Table 50: South American, Middle East & Africa Market for Sexually Transmitted Disease Therapeutics by Drug Class, Through 2023
Table 51: South American Estimated HBsAG Seroprevalence, 2016
Table 52: Latin America Estimated HCV Prevalence, 2016
Table 53: Latin America Estimated HCV Prevalence, 2016
Table 54: Preventive Health Services for Adults Covered by Private Plans Without Cost Sharing
Table 55: Preventive Health Services for Children Covered by Private Plans Without Cost Sharing
Table 56: HIV Pipeline, 2018
Table 57: Gonorrhea Pipeline, 2018
Table 58: Gilead Sciences, Inc. Leading Products Revenue, 2015-2017
Table 59: GlaxoSmithKline Plc. Leading Products Revenue, 2015-2017
Table 60: Merck & Co., Inc. Leading Products Revenue, 2015-2017
Table 61: Leading Products Revenue, 2015-2017
Table 62: Market Share Analysis for Sexually Transmitted Disease Therapeutics
Table 63: Key Patents, Manufacturer, Indication, Approval Date and Expiration
Table 64: Abbott Laboratories Marketed Products
Table 65: Abbott Laboratories Marketed Products, Diagnostics
Table 66: Abbott Laboratories Net Revenue, 2015-2017
Table 67: AbbVie Inc. Marketed Products
Table 68: AbbVie Inc. Net Revenue, 2015-2017
Table 69: Agilent Technologies, Inc. Net Revenue, 2015-2017
Table 70: Becton, Dickinson and Company Marketed Products
Table 71: Biomerieux, Inc. Marketed Products
Table 72: Bio-Rad Laboratories Marketed Products
Table 73: Boehringer Ingelheim GmbH, Net Revenue, 2014-2016
Table 74: Bristol-Myers Squibb Company Marketed Products
Table 75: Bristol-Myers Squibb Company Net Revenue, 2014-2016
Table 76: Gilead Science Inc. Marketed Products
Table 77: Gilead Sciences Inc. Net Revenue, 2014-2016
Table 78: GlaxoSmithKline PLC Marketed Products
Table 79: ViiV Healthcare Group of Companies Marketed Products
Table 80: GlaxoSmithKline PLC Net Revenue, 2014-2016
Table 81: Hoffmann-La Roche Inc. Marketed Products
Table 82: Hoffmann-La Roche Inc. Net Revenue, 2015-2017
Table 83: Hologic, Inc. Marketed Products
Table 84: Hologic Inc. Net Revenue, 2015-2017
Table 85: Janssen Pharmaceuticals, Inc. Marketed Products
Table 86: Johnson & Johnson Inc. Net Revenue, 2014-2016
Table 87: Merck & Co. Inc. Marketed Products
Table 88: Merck & Co. Inc. Net Revenue, 2014-2016
Table 89: Meridian Life Science, Inc. Marketed Products
Table 90: Novartis AG Marketed Products
Table 91: Novartis AG Net Revenue, 2014-2016
Table 92: Pfizer Inc. Marketed Products by Indication
Table 93: Pfizer Inc. Net Revenue, 2015-2017
Table 94: Qiagen N.V Marketed Products
Table 95: Qiagen N.V. Net Revenue, 2015-2017
Table 96: Quidel Corp Marketed Products
Table 97: Thermo Fisher Scientific, Inc. Marketed Products
Table 98: Abbreviations Used in Sexually Transmitted Disease Therapeutics and Diagnostics Market

List of Figures
Summary Figure A: Global Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2017-2023
Summary Figure B: Global Market for Sexually Transmitted Disease Diagnostics, by Test Type, 2017-2023
Figure 1: Estimated Deaths Owing to Infectious and Parasitic Diseases, 2016
Figure 2: Global Historic and Current Gonorrhea Trend, Incidence, in Men, 2012-2014
Figure 3: United States Funding Trend, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2017
Figure 4: Global Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 5: Global Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
Figure 6: Global Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
Figure 7: Global Historic and Current Chlamydia Trend, Incidence, Women, 2012-2014
Figure 8: Global Historic and Current Chlamydia Trend, Incidence, Men, 2012-2014
Figure 9: Global Historic and Current Gonorrhea Trend, Incidence, Men, 2012-2014
Figure 10: Global Historic and Current Gonorrhea Trend, Incidence, Women, 2012-2014
Figure 11: Hepatitis Timeline, 1990-2004
Figure 12: Hepatitis Timeline, 2011-2015
Figure 13: Hepatitis Timeline, 2015-2017
Figure 14: Global Market for Hepatitis Therapeutics, 2017-2023
Figure 15: Global Market for Hepatitis, by Region, 2017-2023
Figure 16: Global Historic and Current HIV Trend, Prevalence, 2012-2016
Figure 17: Estimated HIV Regional Prevalence, 2016
Figure 18: Estimated HIV Regional Incidence, 2016
Figure 19: Global Market for HIV/AIDS Therapeutics, 2017-2023
Figure 20: Global Market for HIV/AIDS Therapeutics, by Region, 2017-2023
Figure 21: United States Syphilis Incidence Among Newborns, 2014-2016
Figure 22: Global Historic and Current Infectious Syphilis Trend, Incidence, Men, 2012-2014
Figure 23: Global Historic and Current Infectious Syphilis Trend, Incidence, Men, 2012-2014
Figure 24: Global Market for Other Therapeutics, 2017-2023
Figure 25: Global Market for Other Therapeutics, by Region, 2017-2023
Figure 26: Global Market for Sexually Transmitted Disease Diagnostics, 2017-2023
Figure 27: Global Market for Sexually Transmitted Disease Diagnostics, by Region, 2017-2023
Figure 28: Global Market Share for Sexually Transmitted Disease Diagnostics, by Test Type, 2018
Figure 29: Global Market Share for Sexually Transmitted Disease Diagnostics, by Test Type, 2023
Figure 30: Global Market for Enzyme Immunoassay (EIA) and ELISA Diagnostics, 2017-2023
Figure 31: Global Market for PCR Diagnostics, 2017-2023
Figure 32: Global Market for Rapid Diagnostic Tests (RDTs) Diagnostics, 2017-2023
Figure 33: Global Market for Other Diagnostics, 2017-2023
Figure 34: Global Market for Antibiotic Drugs, 2017-2023
Figure 35: Global Market for Antibiotic Drugs, by Region, 2017-2023
Figure 36: Global Market for Antiviral/Antiretroviral Drugs, 2017-2023
Figure 37: Global Market for Antiviral/Antiretroviral Drugs, by Region, 2017-2023
Figure 38: Global Market for Other Drug Class, 2017-2023
Figure 39: Global Market for Other Drug Class, by Region, 2017-2023
Figure 40: North American Market for Sexually Transmitted Therapeutics, 2017-2023
Figure 41: North American Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
Figure 42: North American Market for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
Figure 43: North American Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018
Figure 44: North American Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023
Figure 45: North American Market for Sexually Transmitted Disease Therapeutics, by Country, 2017-2023
Figure 46: United States Sexually Transmitted Diseases Incidence, 2016
Figure 47: United States Sexually Transmitted Infections, by Sex, 2016
Figure 48: United States Historic and Current Syphilis Trend, Incidence, 1990-2016
Figure 49: United States Historic and Current Chlamydia Trend, Incidence, 1990-2016
Figure 50: United States Historic and Current Gonorrhea Trend, Incidence, 1990-2016
Figure 51: United States Historic and Current Hepatitis A Trend, Incidence, 2012-2016
Figure 52: United States Historic and Current Acute Hepatitis B Trend, Incidence, 2012-2016
Figure 53: United States Historic and Current Hepatitis C Trend, Incidence, 2012-2016
Figure 54: United States Historic and Current HIV Trend, Incidence, 2011-2016
Figure 55: United States Market for Sexually Transmitted Disease Therapeutics, 2018-2023
Figure 56: Canadian Sexually Transmitted Infections, by Sex, 2014
Figure 57: Canadian Historic and Current Chlamydia Trend, Incidence, 2005-2014
Figure 58: Canadian Historic and Current Gonorrhea Trend, Incidence, by Sex, 2005-2014
Figure 59: Canadian Historic and Current Infectious Syphilis Trend, Incidence, 2005-2014
Figure 60: Canadian Historic and Current Congenital Syphilis Trend, Incidence, 2005-2014
Figure 61: Canadian Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 62: Mexican Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 63: European Historic and Current Chlamydia Trend, Incidence, 2012-2015
Figure 64: European Historic and Current AIDS Trend, Incidence, 2007-2011
Figure 65: European Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 66: European Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
Figure 67: European Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
Figure 68: European Market for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018
Figure 69: European Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023
Figure 70: European Market for Sexually Transmitted Disease Therapeutics, by Country, 2017-2023
Figure 71: United Kingdom HIV Incidence, Gay and Bisexual Men, 2015 and 2016
Figure 72: United Kingdom Historic and Current Gonorrhea Trend, Incidence, 2011-2015
Figure 73: United Kingdom Historic and Current Hepatitis B Trend, Incidence, 2012-2016
Figure 74: United Kingdom Historic and Current Hepatitis C Trend, Incidence, 2012-2016
Figure 75: United Kingdom Market for Sexually Transmitted Disease Therapeutics, 2018-2023
Figure 76: German Historic and Current Hepatitis B Trend, Incidence, 2012-2016
Figure 77: German Historic and Current Hepatitis C Trend, Incidence, 2012-2016
Figure 78: German Market for Sexually Transmitted Disease Therapeutics, 2018-2023
Figure 79: French Historic and Current Chlamydia Trend, Incidence, 2011-2015
Figure 80: French Historic and Current Gonorrhea Trend, Incidence, 2011-2015
Figure 81: French Historic and Current Hepatitis B Trend, Incidence, 2012-2016
Figure 82: French Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 83: Spain Historic and Current Chlamydia Trend, Incidence, 2011-2015
Figure 84: Spain Historic and Current Gonorrhea Trend, Incidence, 2011-2015
Figure 85: Spain Historic and Current Hepatitis B Trend, Incidence, 2012-2016
Figure 86: Spain Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 87: Italian Historic and Current Chlamydia Trend, Incidence, 2011-2015
Figure 88: Italian Historic and Current Gonorrhea Trend, Incidence, 2011-2015
Figure 89: Italian Historic and Current Hepatitis B Trend, Incidence, 2012-2016
Figure 90: Italian Historic and Current Hepatitis C Trend, Incidence, 2012-2016
Figure 91: Italian Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 92: Denmark Historic and Current Chlamydia Trend, Incidence, 2011-2015
Figure 93: The Netherlands Historic and Current Chlamydia Trend, Incidence, 2011-2015
Figure 94: Denmark Historic and Current Gonorrhea Trend, Incidence, 2011-2016
Figure 95: Ireland Historic and Current Gonorrhea Trend, Incidence, 2011-2015
Figure 96: The Netherlands Historic and Current Hepatitis B Trend, Incidence, 2012-2016
Figure 97: Sweden Historic and Current Hepatitis B Trend, Incidence, 2012-2016
Figure 98: Sweden Historic and Current Hepatitis C Trend, Incidence, 2012-2016
Figure 99: Poland Historic and Current Hepatitis C Trend, Incidence, 2012-2016
Figure 100: Rest of Europe Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 101: Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 102: Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
Figure 103: Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
Figure 104: Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018
Figure 105: Asia-Pacific Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023
Figure 106: Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, by Country, 2017-2023
Figure 107: Chinese Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 108: Japanese Historic and Current HIV/AIDS Infections, Incidence, 2001-2016
Figure 109: Japanese Historic and Current Chlamydia Trend, Incidence, 2000-2014
Figure 110: Japanese Historic and Current Genital Herpes Trend, Incidence, 2000-2014
Figure 111: Japanese Historic and Current Gonorrhea Trend, Incidence, 2000-2014
Figure 112: Japanese Historic and Current Syphilis Trend, Incidence, 2008-2014
Figure 113: Japanese Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 114: Indian Historic and Current HIV Trend, Incidence, 2005-2016
Figure 115: Indian Historic and Current HIV Trend, Prevalence, 2005-2016
Figure 116: Indian Historic and Current AIDS, Mortality, 2005-2016
Figure 117: Indian Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 118: South Korean Historic and Current HIV/AIDS Infections, Incidence, 2001-2016
Figure 119: South Korean Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 120: Australia Historic and Current HIV Trend, Incidence, 2012-2014
Figure 121: Australia Mode of HIV Transmission, 2015
Figure 122: Australia Historic and Current Hepatitis C Trend, Incidence, 2007-2014
Figure 123: Australia Historic and Current Hepatitis B Trend, Incidence, 2007-2014
Figure 124: Singapore Historic and Current HIV/AIDS Infections, Incidence, 2001-2015
Figure 125: Republic of Korea Historic and Current HIV/AIDS Infections, Incidence, 2001-2016
Figure 126: Rest of Asia-Pacific Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 127: HBV Prevalence, by Region, 2015
Figure 128: HCV Infection, by Region, 2015
Figure 129: HCV Prevalence, by Region, 2015
Figure 130: South American, Middle East & Africa Market for Sexually Transmitted Disease Therapeutics, 2017-2023
Figure 131: South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2018
Figure 132: South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Disease Area, 2023
Figure 133: South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2018
Figure 134: South American, Middle East & Africa Market Share for Sexually Transmitted Disease Therapeutics, by Drug Class, 2023
Figure 135: Gilead Sciences, Inc. Antiviral Sales, 2015-2017
Figure 136: Abbott Laboratories, Revenue Share, by Region, 2017
Figure 137: Abbott Laboratories Revenue Share, by Business Segment, 2017
Figure 138: AbbVie Inc. Revenue Share, by Region, 2016
Figure 139: Agilent Technologies, Inc. Revenue Share, by Region, 2017
Figure 140: Agilent Technologies, Inc. Revenue Share, by Business Segment, 2017
Figure 141: Becton, Dickinson and Company Financial Performance, 2013-2017
Figure 142: Becton, Dickinson and Company Revenue Share, by Business Segment, 2017
Figure 143: Becton, Dickinson and Company Revenue Share, by Region, 2017
Figure 144: Boehringer Ingelheim GmbH Revenue Share, by Region, 2016
Figure 145: Boehringer Ingelheim GmbH Revenue Share, by Business Segment, 2016
Figure 146: Boehringer Ingelheim GmbH R&D Expenditure, 2014-2016
Figure 147: Bristol-Myers Squibb Company Revenue Share, by Region, 2016
Figure 148: Bristol-Myers Squibb Company Revenue Share, by Business Segment, 2016
Figure 149: Gilead Sciences Inc. Revenue Share, by Business Segment, 2016
Figure 150: Gilead Sciences Inc. Revenue Share, by Region, 2016
Figure 151: GlaxoSmithKline PLC Revenue Share by Business Segment, 2016
Figure 152: GlaxoSmithKline PLC Revenue Share, by Region, 2016
Figure 153: Hoffmann-La Roche Inc. Revenue Share, by Segment, 2017
Figure 154: Hoffmann-La Roche Inc. Revenue Share, by Region, 2017
Figure 155: Johnson & Johnson Inc. Revenue Share, by Business Segment, 2016
Figure 156: Johnson & Johnson Inc. Revenue Share, by Region, 2016
Figure 157: Merck & Co. Inc. Revenue Share, by Business Segment, 2016
Figure 158: Merck & Co. Inc. Revenue Share, by Region, 2016
Figure 159: Novartis AG Revenue Share, by Region, 2016
Figure 160: Novartis AG Revenue Share, by Business Segment, 2016
Figure 161: Pfizer Inc. Revenue Share, by Region, 2016
Figure 162: Pfizer Inc. Revenue Share by Business Segment, 2016
Figure 163: Qiagen N.V Revenue Share, by Region, 2017
Figure 164: Qiagen N.V Revenue Share, by Business Segment, 2017
Figure 165: Thermo Fisher Scientific, Inc. Revenue Share, by Region, 2016
Figure 166: Thermo Fisher Scientific, Inc. Revenue Share, by Business Segment, 2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories
  • Abbvie Inc.
  • Agilent Technologies, Inc.
  • Becton, Dickinson And Company
  • Bio-Rad Laboratories, Inc
  • Biomerieux, Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Cepheid Inc.
  • Gilead Sciences, Inc.
  • Glaxosmithkline Plc.
  • Hoffmann-La Roche Inc.
  • Hologic Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Meridian Life Science Inc.
  • Novartis Ag
  • Pfizer Inc.
  • Promega Corp.
  • Qiagen N.V.
  • Quidel Corp
  • Thermo Fisher Scientific, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4616790
Adroll
adroll